Table 2 Characteristics of the study population by severity of hypophosphataemia
From: Clinical factors associated with severe hypophosphataemia after kidney transplant
Variable | Severe hypophosphataemia (≤0.3 mmol/L, n = 199) | Mild-moderate hypophosphataemia (0.31–0.69 mmol/L, n = 1411) | No hypophosphataemia (≥0.7 mmol/L, n = 228) | P-value |
|---|---|---|---|---|
Epidemiological | ||||
 Recipient sex (% Female) | 40.2% | 40.3% | 37.2% | 0.69 |
 Median age at transplant (years [IQR]) | 45 (35–54) | 48 (37–57) | 49 (41–59) | 0.004 |
 Donor sex (% Female) | 46.3% | 49.9% | 49.5% | 0.70 |
 Median donor age (years [IQR]) | 47 (36–58) | 50 (38–58) | 56 (45–64) | <0.001 |
 Transplant type (% deceased donor) | 61.8% | 72.8% | 89.9% | <0.001 |
Biochemical | ||||
 Median pre-transplant phosphate (mmol/L [IQR]) | 1.69 (1.45–1.95) | 1.65 (1.38–1.97) | 1.56 (1.26–1.94) | 0.059 |
 Median pre-transplant adjusted calcium (mmol/L [IQR]) | 2.42 (2.33–2.51) | 2.40 (2.29–2.50) | 2.36 (2.22–2.48) | 0.001 |
 Median pre-transplant alkaline phosphatase (U/L [IQR]) | 86 (64–145) | 109 (76–176) | 126 (81–187) | <0.001 |
 Median pre-transplant PTH (xULN [IQR]) | 5.7 (3.1–9.5) | 5.9 (3.1–10.1) | 5.6 (2.3–10.6) | 0.53 |
 Median serum creatinine 7–10 days post-transplant (μmol/L [IQR]) | 123 (90–232) | 201 (123–467) | 522 (302–730) | <0.001 |
Clinical | ||||
 Median duration of RRT pre-transplant (years [IQR]) | 1.64 (0.70–2.95) | 1.90 (0.75–3.745) | 2.55 (0.91–4.43) | 0.016 |
 Parathyroidectomy pre-transplant (%) | 2.0% | 8.6% | 22.8% | <0.001 |
 On alfacalcidol or calcitriol pre-transplant (%) | 57.8% | 54.2% | 58.8% | 0.50 |
 On cinacalcet pre-transplant (%) | 10.6% | 11.7% | 7.9% | 0.50 |
 Era of immunosuppression (% pre-01/01/2007) | 24.1% | 30.4% | 35.5% | 0.059 |
 Delayed graft function | 10.1% | 18.0% | 42.1% | <0.001 |